Press Releases 2012


 
2014 | 2013 | 2012 | 2011
DateTitle 
December 19, 2012Incyte to Present at the 31st Annual J. P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 19, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 31st Annual J. P. Morgan Healthcare Conference on Monday, January 7th at 8:30 a.m. (PST) / 11:30 a.m. (EST) in San Francisco. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investo... 
Printer Friendly Version
December 10, 2012New Data for Jakafi® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting
In long-term results from two randomized Phase III clinical trials (COMFORT-I and COMFORT-II), patients with myelofibrosis treated with Jakafi had improved survival over placebo and best available therapy, suggesting an overall survival benefit Data from an ongoing Phase II trial suggest that long-term treatment with Jakafi may be a durably efficacious therapy for patients with polycythemia vera ... 
Printer Friendly Version
December 07, 2012New Data for Jakafi® (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
Incyte to host a webcast for investors featuring highlights from multiple presentations on Monday, Dec. 10 at 8:45 p.m. EST WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 7, 2012-- Incyte Corporation (Nasdaq: INCY) announced today that several analyses from clinical studies of Jakafi® (ruxolitinib) will be presented at the 2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to 11 at the Georgia World Congress Center in Atlanta. Jaka... 
Printer Friendly Version
November 28, 2012Incyte to Present at the Oppenheimer 23rd Annual Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 28, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Oppenheimer 23rd Annual Healthcare Conference on Thursday, December 13 at 1:35 p.m. (EST) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in listen... 
Printer Friendly Version
November 19, 2012Incyte to Present at the 24th Annual Piper Jaffray Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 19, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27th at 1:30 p.m. (EST) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 60 days. Investors interested in lis... 
Printer Friendly Version
November 15, 2012Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 15, 2012-- Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incyte’s oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Co... 
Printer Friendly Version
November 13, 2012Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
- Baricitinib advancing into Phase III trials for rheumatoid arthritis - Lilly and Incyte to host a webcast for investors featuring these results today, Nov. 13 at 7 p.m. ET WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis... 
Printer Friendly Version
November 05, 2012Incyte to Present at the Jefferies 2012 Global Healthcare Conference (London)
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 5, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Jefferies 2012 Global Healthcare Conference on Thursday, November 15 at 3:00 p.m. (GMT) / 10:00 a.m. (EST) in London. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in... 
Printer Friendly Version
November 01, 2012Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs
$43.7 million of Jakafi® (ruxolitinib) recognized as third-quarter U.S. net product revenue including $9.0 million of previously deferred revenue Third quarter dispenses to patients increased 16 percent over second quarter Ruxolitinib approved for use in the European Union Conference Call Scheduled Today at 8:30 a.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2012--... 
Printer Friendly Version
October 22, 2012Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 22, 2012-- Incyte Corporation (Nasdaq:INCY) today announced that Jim Daly has joined Incyte as Executive Vice President and Chief Commercial Officer, reporting to Paul Friedman, M.D., Incyte's President and Chief Executive Officer. Formerly Senior Vice President, North America Commercial Operations at Amgen, Mr. Daly is joining Incyte effective today and will serve on the executive leadership team, assuming res... 
Printer Friendly Version
October 09, 2012Incyte to Report Third Quarter 2012 Financial Results on November 1
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 9, 2012-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2012 financial results conference call for 8:30 a.m. ET on Thursday, November 1, 2012. The schedules for the press release and conference call are as follows:       ... 
Printer Friendly Version
September 19, 2012National Myelofibrosis Awareness Day to Launch on September 20
Patient advocacy coalition leads inaugural recognition day to raise awareness about myelofibrosis, a rare, potentially life-threatening blood cancer WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 19, 2012-- Incyte Corporation (Nasdaq: INCY) today announced its support of the first national Myelofibrosis Awareness Day, which will be held on Sept. 20, 2012. The inaugural recognition day is being led by the MPN Coalition, a group of patient advo... 
Printer Friendly Version
August 28, 2012Jakavi® (ruxolitinib) First Medication to Receive European Commission Approval to Treat Patients with Myelofibrosis
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 28, 2012-- Incyte Corporation (Nasdaq: INCY) today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi® (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythem... 
Printer Friendly Version
August 23, 2012Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 23, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of September: Robert W. Baird & Co. 2012 Health Care Conference on Wednesday, September 5, 2012 at 10:10 a.m. (ET) in New York City; Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2012 at 10:55 a.m. (ET) in New Yor... 
Printer Friendly Version
August 03, 2012Incyte to Present at the 32nd Annual Canaccord Genuity Growth Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 3, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 32nd Annual Canaccord Genuity Growth Conference on Wednesday, August 15 at 10:30 a.m. (ET) in Boston. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in listenin... 
Printer Friendly Version
August 02, 2012Incyte Reports 2012 Second-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs
$35.1 million of Jakafi® (ruxolitinib) shipped to specialty pharmacies during the second quarter; $29.7 million in second-quarter net product revenue based on the sell-through revenue recognition method* Use of Jakafi to treat patients with intermediate or high-risk myelofibrosis further supported by multiple clinical presentations Positive Phase IIb results of oral JAK1 and JAK2 inhibitor, baricitinib, in patients with active rheumatoid arthritis presented at EULAR Conference Call Schedul... 
Printer Friendly Version
July 16, 2012Incyte to Report Second Quarter 2012 Financial Results on August 2
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 16, 2012-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2012 financial results conference call for 8:30 a.m. ET on Thursday, August 2, 2012. The schedules for the press release and conference call are as follows:     -- Q2 2012... 
Printer Friendly Version
June 26, 2012Incyte to Present at the JMP Securities 7th Annual Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 26, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the JMP Securities 7th Annual Healthcare Conference on Thursday, July 12, 2012 at 12:00 p.m. (ET) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in li... 
Printer Friendly Version
June 08, 2012Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Results presented as a late breaker at EULAR 2012 BERLIN, June 8, 2012 /PRNewswire via COMTEX/ --Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (... 
Printer Friendly Version
June 04, 2012Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO
Data demonstrate that INCB024360 achieves greater than 90 percent IDO1 inhibition at generally well-tolerated doses and may represent a new treatment for advanced malignancies CHICAGO--(BUSINESS WIRE)--Jun. 4, 2012-- Incyte Corporation (Nasdaq: INCY) presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of ... 
Printer Friendly Version
June 04, 2012New Data for Jakafi® (ruxolitinib) Presented at 2012 ASCO Annual Meeting
Data from an ongoing trial suggest a dosing strategy with Jakafi that may be efficacious and well-tolerated in myelofibrosis patients with low platelet counts Further analysis of adverse events from Phase III data in COMFORT-I indicates there is no withdrawal syndrome after discontinuation of therapy with Jakafi Phase III data from COMFORT-II provide further evidence that patients wit... 
Printer Friendly Version
May 23, 2012Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May. 23, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of June: Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012 at 3:20 pm (PT) / 6:20 pm (ET) in Rancho Palos Verdes; Jefferies 2012 Global Healthcare Conference on Thursday, June 7, 2012 at 11:00 am (ET) i... 
Printer Friendly Version
May 01, 2012Incyte to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
WILMINGTON, Del., May 01, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today it will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 11:20 a.m. (PT) / 2:20 p.m. (ET) in Las Vegas. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in ... 
Printer Friendly Version
April 26, 2012Incyte Reports 2012 First-Quarter Financial Results; Updates Shareholders on Commercial Activity and Key Clinical Programs
$19.3 million in first-quarter net product revenue from JakafiTM (ruxolitinib); $25.1 million of Jakafi shipped to specialty pharmacies during the quarter Phase III studies of Jakafi published in The New England Journal of Medicine demonstrate significant clinical benefit for patients with myelofibrosis Conference Call Scheduled Today at 8:30 a.m. ET WILMINGTON, Del., Apr 26, ... 
Printer Friendly Version
April 20, 2012Incyte Announces EU Regulatory Milestone for Ruxolitinib
WILMINGTON, Del., Apr 20, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today a European Union (EU) regulatory milestone from Novartis. The milestone includes a $40 million payment earned based on the recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for approval of ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary ... 
Printer Friendly Version
April 10, 2012Incyte to Report First Quarter 2012 Financial Results on April 26
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 10, 2012-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2012 financial results conference call for 8:30 a.m. ET on Thursday, April 26, 2012. The schedules for the press release and conference call are as follows:         ... 
Printer Friendly Version
February 29, 2012Phase III studies of Jakafi™ (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis
Results from the COMFORT-I and COMFORT-II Phase III trials show Jakafi significantly reduced spleen volume and debilitating symptoms associated with myelofibrosis (MF), a life-threatening blood cancer Updated analysis from COMFORT-I suggests Jakafi may provide an overall survival benefit as compared to placebo WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 29, 2012-- The New England Journal of Medicine (NEJM... 
Printer Friendly Version
February 22, 2012Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 22, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March: Cowen and Company’s 32nd Annual Health Care Conference on Monday, March 5, 2012 at 2:10 p.m. (ET) in Boston; and Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13, 2012 at 2:00 p.m. (ET) in Miami ... 
Printer Friendly Version
February 15, 2012Incyte Reports 2011 Fourth-Quarter and Full-Year Financial Results; Provides 2012 Financial Guidance; Updates Shareholders on Key Clinical Programs
Jakafi™ (ruxolitinib) approved by the FDA for treatment of patients with intermediate or high-risk myelofibrosis on November 16, 2011 $2.0 million in net fourth-quarter revenue from Jakafi and $2.3 million in net deferred revenue; $4.9 million of Jakafi shipped to specialty pharmacies Clinical benefits of Jakafi discussed in multiple presentations at 2011 ASH Annual Meeting ... 
Printer Friendly Version
February 03, 2012Incyte to Present at the Leerink Swann 2012 Global Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 3, 2012-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 2:30 p.m. (ET) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in ... 
Printer Friendly Version
January 26, 2012Incyte to Report Fourth Quarter/Year-End 2011 Financial Results on February 15
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 26, 2012-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter/year-end 2011 financial results conference call for 8:30 a.m. ET on Wednesday, February 15, 2012. The schedules for the press release and conference call are as follows: -- Q4 & YE 2011 Press Release:     ... 
Printer Friendly Version